RÉSUMÉ
Inflammation and autoimmune responses contribute to the pathophysiology of Long COVID, and its affective and chronic fatigue syndrome symptoms, labeled "the physio-affective phenome." To investigate whether Long COVID and its physio-affective phenome are linked to autoimmunity to the tight junction proteins, zonulin and occludin (ZOOC), and immune reactivity to lipopolysaccharides (LPS), and whether the latter are associated with signs of human herpes virus-6 (HHV-6) reactivation, autoimmunity directed against oligodendrocyte and neuronal proteins, including myelin basic protein. IgA/IgM/IgG responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), HHV-6, ZOOC, and neuronal proteins, C-reactive protein (CRP), and advanced oxidation protein products (AOPPs), were measured in 90 Long COVID patients and 90 healthy controls. The physio-affective phenome was conceptualized as a factor extracted from physical and affective symptom domains. Neural network identified IgA directed to LPS (IgA-LPS), IgG-ZOOC, IgG-LPS, and IgA-ZOOC as important variables associated with Long COVID diagnosis with an area under the ROC curve of 0.755. Partial Least Squares analysis showed that 40.9% of the variance in the physio-affective phenome was explained by CRP, IgA-myelin basic protein (MBP), and IgG-MBP. A large part of the variances in both autoimmune responses to MBP (36.3%-39.7%) was explained by autoimmunity (IgA and IgG) directed to ZOOC. The latter was strongly associated with indicants of HHV-6 reactivation, which in turn was associated with increased IgM-SARS-CoV-2. Autoimmunity against components of the tight junctions and increased bacterial translocation may be involved in the pathophysiology of Long COVID's physio-affective phenome.
Sujet(s)
Auto-immunité , COVID-19 , Syndrome de fatigue chronique , Herpèsvirus humain de type 6 , Inflammation , Jonctions serrées , Humains , Syndrome de fatigue chronique/immunologie , Syndrome de fatigue chronique/virologie , Herpèsvirus humain de type 6/immunologie , Femelle , Mâle , Adulte d'âge moyen , Jonctions serrées/immunologie , COVID-19/immunologie , Inflammation/immunologie , Adulte , Occludine , Dépression/immunologie , SARS-CoV-2/immunologie , Sujet âgé , Immunoglobuline G/sang , Syndrome de post-COVID-19 , Immunoglobuline A/sang , Lipopolysaccharides/immunologie , Autoanticorps/sang , Autoanticorps/immunologie , Anticorps antiviraux/sang , Infections à roséolovirus/immunologie , Infections à roséolovirus/complications , Infections à roséolovirus/virologie , Haptoglobines , Précurseurs de protéinesSujet(s)
Herpèsvirus humain de type 6 , Immunothérapie adoptive , Récepteurs chimériques pour l'antigène , Infections à roséolovirus , Humains , Herpèsvirus humain de type 6/immunologie , Immunothérapie adoptive/effets indésirables , Immunothérapie adoptive/méthodes , Récepteurs chimériques pour l'antigène/immunologie , Infections à roséolovirus/immunologie , Infections à roséolovirus/complications , Lymphocytes T/immunologie , Mâle , FemelleRÉSUMÉ
Synergistic interactions between human herpesvirus 6A (HHV-6A) and Epstein-Barr virus (EBV) are hypothesized in the etiopathogenesis of multiple sclerosis (MS). This study investigated if HHV-6A and EBV seroreactivities interact regarding the risk of developing MS. Antibodies against viral antigens were analyzed in biobank samples from 670 individuals who later developed MS and matched controls. Additive interactions were analyzed. A significant interaction between HHV-6A and EBNA-1 seroreactivities was observed in study participants above the median age of 24.9 years (attributable proportion due to interaction = 0.45). This finding supports the hypothesis that HHV-6A and EBV infections interact in MS development. ANN NEUROL 2024;96:302-305.
Sujet(s)
Anticorps antiviraux , Infections à virus Epstein-Barr , Antigènes nucléaires du virus d'Epstein-Barr , Herpèsvirus humain de type 4 , Herpèsvirus humain de type 6 , Sclérose en plaques , Infections à roséolovirus , Humains , Herpèsvirus humain de type 6/immunologie , Sclérose en plaques/virologie , Sclérose en plaques/immunologie , Herpèsvirus humain de type 4/immunologie , Femelle , Études cas-témoins , Mâle , Adulte , Infections à virus Epstein-Barr/immunologie , Infections à virus Epstein-Barr/complications , Anticorps antiviraux/sang , Anticorps antiviraux/immunologie , Antigènes nucléaires du virus d'Epstein-Barr/immunologie , Infections à roséolovirus/immunologie , Infections à roséolovirus/complications , Jeune adulte , Adulte d'âge moyen , AdolescentRÉSUMÉ
BACKGROUND: Persistent infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), reactivation of dormant viruses, and immune-oxidative responses are involved in long COVID. OBJECTIVES: To investigate whether long COVID and depressive, anxiety, and chronic fatigue syndrome (CFS) symptoms are associated with IgA/IgM/IgG to SARS-CoV-2, human herpesvirus type 6 (HHV-6), Epstein-Barr Virus (EBV), and immune-oxidative biomarkers. METHODS: We examined 90 long COVID patients and ninety healthy controls. We measured serum IgA/IgM/IgG against HHV-6 and EBV and their deoxyuridine 5'-triphosphate nucleotidohydrolase (duTPase), SARS-CoV-2, and activin-A, C-reactive protein (CRP), advanced oxidation protein products (AOPP), and insulin resistance (HOMA2-IR). RESULTS: Long COVID patients showed significant elevations in IgG/IgM-SARS-CoV-2, IgG/IgM-HHV-6, and HHV-6-duTPase, IgA/IgM-activin-A, CRP, AOPP, and HOMA2-IR. Neural network analysis yielded a highly significant predictive accuracy of 80.6% for the long COVID diagnosis (sensitivity: 78.9%, specificity: 81.8%, area under the ROC curve = 0.876); the topmost predictors were as follows: IGA-activin-A, IgG-HHV-6, IgM-HHV-6-duTPase, IgG-SARS-CoV-2, and IgM-HHV-6 (all positively) and a factor extracted from all IgA levels to all viral antigens (inversely). The top 5 predictors of affective symptoms due to long COVID were IgM-HHV-6-duTPase, IgG-HHV-6, CRP, education, IgA-activin-A (predictive accuracy of r = 0.636). The top 5 predictors of CFS due to long COVID were in descending order: CRP, IgG-HHV-6-duTPase, IgM-activin-A, IgM-SARS-CoV-2, and IgA-activin-A (predictive accuracy: r = 0.709). CONCLUSION: Reactivation of HHV-6, SARS-CoV-2 persistence, and autoimmune reactions to activin-A combined with activated immune-oxidative pathways play a major role in the pathophysiology of long COVID as well as the severity of its affective symptoms and CFS.
Sujet(s)
Activines , COVID-19 , Syndrome de fatigue chronique , Herpèsvirus humain de type 6 , Immunoglobuline A , Immunoglobuline M , SARS-CoV-2 , Humains , Herpèsvirus humain de type 6/immunologie , Syndrome de fatigue chronique/sang , Syndrome de fatigue chronique/immunologie , Syndrome de fatigue chronique/virologie , Mâle , Femelle , Immunoglobuline A/sang , Immunoglobuline M/sang , COVID-19/immunologie , COVID-19/sang , Adulte , Activines/sang , Adulte d'âge moyen , SARS-CoV-2/immunologie , Syndrome de post-COVID-19 , Anticorps antiviraux/sang , Herpèsvirus humain de type 4/immunologie , Marqueurs biologiques/sang , Infections à roséolovirus/sang , Infections à roséolovirus/immunologieRÉSUMÉ
ABSTRACT: Human herpesvirus 6B (HHV-6B) reactivation and disease are increasingly reported after chimeric antigen receptor (CAR) T-cell therapy (CARTx). HHV-6 reactivation in the CAR T-cell product was recently reported, raising questions about product and patient management. Because of overlapping manifestations with immune effector cell-associated neurotoxicity syndrome, diagnosing HHV-6B encephalitis is challenging. We provide 2 lines of evidence assessing the incidence and outcomes of HHV-6B after CARTx. First, in a prospective study with weekly HHV-6B testing for up to 12 weeks after infusion, HHV-6B reactivation occurred in 8 of 89 participants; 3 had chromosomally integrated HHV-6 and were excluded, resulting in a cumulative incidence of HHV-6B reactivation of 6% (95% confidence interval [CI], 2.2-12.5). HHV-6B detection was low level (median peak, 435 copies per mL; interquartile range, 164-979) and did not require therapy. Second, we retrospectively analyzed HHV-6B detection in the blood and/or cerebrospinal fluid (CSF) within 12 weeks after infusion in CARTx recipients. Of 626 patients, 24 had symptom-driven plasma testing, with detection in 1. Among 34 patients with CSF HHV-6 testing, 1 patient had possible HHV-6 encephalitis for a cumulative incidence of 0.17% (95% CI, 0.02-0.94), although symptoms improved without treatment. Our data demonstrate that HHV-6B reactivation and disease are infrequent after CARTx. Routine HHV-6 monitoring is not warranted.
Sujet(s)
Herpèsvirus humain de type 6 , Immunothérapie adoptive , Récepteurs chimériques pour l'antigène , Infections à roséolovirus , Activation virale , Humains , Herpèsvirus humain de type 6/immunologie , Mâle , Femelle , Adulte d'âge moyen , Adulte , Infections à roséolovirus/immunologie , Infections à roséolovirus/virologie , Infections à roséolovirus/thérapie , Infections à roséolovirus/diagnostic , Récepteurs chimériques pour l'antigène/immunologie , Activation virale/immunologie , Immunothérapie adoptive/méthodes , Immunothérapie adoptive/effets indésirables , Sujet âgé , Études prospectives , Études rétrospectives , Jeune adulte , IncidenceRÉSUMÉ
HHV-6B reactivation affects approximately half of all allogeneic hematopoietic cell transplant (HCT) recipients. HHV-6B is the most frequent infectious cause of encephalitis following HCT and is associated with pleiotropic manifestations in this setting, including graft-versus-host disease, myelosuppression, pneumonitis, and CMV reactivation, although the causal link is not always clear. When the virus inserts its genome in chromosomes of germ cells, the chromosomally integrated form (ciHHV6) is inherited by offspring. The condition of ciHHV6 is characterized by the persistent detection of HHV-6 DNA, often confounding diagnosis of reactivation and disease-this has also been associated with adverse outcomes. Recent changes in clinical practice in the field of cellular therapies, including a wider use of post-HCT cyclophosphamide, the advent of letermovir for CMV prophylaxis, and the rapid expansion of novel cellular therapies require contemporary epidemiological studies to determine the pathogenic role and spectrum of disease of HHV-6B in the current era. Research into the epidemiology and clinical significance of HHV-6B in chimeric antigen receptor T cell (CAR-T cell) therapy recipients is in its infancy. No controlled trials have determined the optimal treatment for HHV-6B. Treatment is reserved for end-organ disease, and the choice of antiviral agent is influenced by expected toxicities. Virus-specific T cells may provide a novel, less toxic therapeutic modality but is more logistically challenging. Preventive strategies are hindered by the high toxicity of current antivirals. Ongoing study is needed to keep up with the evolving epidemiology and impact of HHV-6 in diverse and expanding immunocompromised patient populations.
Sujet(s)
Transplantation de cellules souches hématopoïétiques , Herpèsvirus humain de type 6 , Récepteurs chimériques pour l'antigène , Infections à roséolovirus , Activation virale , Herpèsvirus humain de type 6/immunologie , Herpèsvirus humain de type 6/génétique , Herpèsvirus humain de type 6/physiologie , Humains , Transplantation de cellules souches hématopoïétiques/effets indésirables , Infections à roséolovirus/virologie , Infections à roséolovirus/immunologie , Infections à roséolovirus/thérapie , Récepteurs chimériques pour l'antigène/immunologie , Récepteurs chimériques pour l'antigène/génétique , Immunothérapie adoptive/méthodes , Immunothérapie adoptive/effets indésirables , Maladie du greffon contre l'hôte/immunologie , Maladie du greffon contre l'hôte/étiologieRÉSUMÉ
Human herpesvirus 7 (HHV-7) is a T-lymphotropic virus isolated from peripheral blood mononuclear cells as beta herpes viruses. It is a highly prevalent virus since over 90% of adults are seropositive. The majority of primary infection occurs in early childhood, and its prevalence peaks at 60 % in 11-13-year-old. This study was designed to investigate the seroprevalence of HHV- 7 infections among apparently healthy children as well as child patients with fever and skin rash in the Diyala community and its association with certain socio-demographic variables. The current study is a cross-sectional study conducted in Diyala province-Iraq, extending from July 2020 to March 2021. A total of 180 child patients with fever and skin rash were included. Their age range was 1-14years. Additionally, 60 healthy age-matched children were enrolled as a control group. A special questionnaire was prepared for this study, including socio-demographic information, clinical notes and the results of a complete blood count. Human privacy was esteemed by obtaining parents' verbal approval. Blood specimen was aspirated from all study groups. Sera were separated and kept at -20 °C until tested. Enzyme-linked immunosorbent assay (ELISA) kits for the detection of anti-HHV-7 IgG were used (Mybiosource-China). Statistical analysis was done using Statistical Package of Social Science (SPSS) version 27, and the P value was considered significant wherever it was less than 0.05. The anti-HHV-7 IgG positivity rate in patients was 19.4%, and that in healthy individuals was 31.7%, with an insignificant difference (P=0.051). The highest HHV-7 IgG positivity rate was found among patients 1-4 years old, matching that in the healthy group with a statistically insignificant difference (P=0.675). The gender, residence and number of children/ family insignificantly affect the distribution of HHV-7 IgG in the control group. The mean±SD of hemoglobulin (Hb) concentration among participants with negative anti-HHV-7 IgG was insignificant compared to their positive counterparts (P=0.987). The mean±SD of total WBC count among those positive for anti-HHV-7 IgG was insignificantly higher than their negative counterpart (P=0.945). The mean±SD lymphocyte count in patients and healthy control positive for anti-HHV-7 IgG were insignificantly higher (P=0.241) and (P=0.344), respectively. Lastly, healthy control positive for anti-HHV-7 IgG had insignificantly higher lymphocyte count (P=0.710). About one-third of healthy children in our community were seropositive for anti-HHV 7 IgG antibodies that are most prevalent at 1-4 years old and are insignificantly associated with gender, residence, and the number of children per family. Furthermore, the HHV-7 infection is insignificantly associated with alterations of complete blood count parameters.
Sujet(s)
Anticorps antiviraux , Exanthème , Infections à roséolovirus , Adolescent , Enfant , Enfant d'âge préscolaire , Humains , Nourrisson , Anticorps antiviraux/sang , Études transversales , Exanthème/épidémiologie , Immunoglobuline G , Iraq/épidémiologie , Agranulocytes , Prévalence , Études séroépidémiologiques , Herpèsvirus humain de type 7 , Infections à roséolovirus/immunologieRÉSUMÉ
Roseoloviruses (human herpesvirus 6A [HHV-6A], -6B, and -7) infect >90% of the human population during early childhood and are thought to remain latent or persistent throughout the life of the host. As such, these viruses are among the most pervasive and stealthy of all viruses; they must necessarily excel at escaping immune detection throughout the life of the host, and yet, very little is known about how these viruses so successfully escape host defenses. Here, we characterize the expression, trafficking, and posttranslational modifications of the HHV6B U20 gene product, which is encoded within a block of genes unique to the roseoloviruses. HHV-6B U20 trafficked slowly through the secretory system, receiving several posttranslational modifications to its N-linked glycans, indicative of surface-expressed glycoproteins, and eventually reaching the cell surface before being internalized. Interestingly, U20 is also phosphorylated on at least one Ser, Thr, or Tyr residue. These results provide a framework to understand the role(s) of U20 in evading host defenses. IMPORTANCE The roseolovirus U20 proteins are virus-encoded integral membrane glycoproteins possessing class I major histocompatibility complex (MHC)-like folds. Surprisingly, although U20 proteins from HHV-6A and -6B share 92% identity, recent studies ascribe different functions to HHV6A U20 and HHV6B U20. HHV6A U20 was shown to downregulate NKG2D ligands, while HHV6B U20 was shown to inhibit tumor necrosis factor alpha (TNF-α)-induced apoptosis during nonproductive infection with HHV6B (E. Kofod-Olsen, K. Ross-Hansen, M. H. Schleimann, D. K. Jensen, et al., J Virol 86:11483-11492, 2012, https://doi.org/10.1128/jvi.00847-12; A. E. Chaouat, B. Seliger, O. Mandelboim, D. Schmiedel, Front Immunol 12:714799, 2021, https://doi.org/10.3389/fimmu.2021.714799). Here, we have performed cell biological and biochemical characterization of the trafficking, glycosylation, and posttranslational modifications occurring on HHV6B U20.
Sujet(s)
Glycoprotéines membranaires , Infections à roséolovirus , Protéines virales , Humains , Herpèsvirus humain de type 6/génétique , Herpèsvirus humain de type 6/immunologie , Glycoprotéines membranaires/génétique , Glycoprotéines membranaires/métabolisme , Infections à roséolovirus/immunologie , Infections à roséolovirus/virologie , Protéines virales/génétique , Protéines virales/immunologie , Échappement immunitaireRÉSUMÉ
HHV-6A is a neurotropic herpesvirus able to infect several CNS cells including astrocytes and primary neurons. Here we found that HHV-6A infection of astrocytoma cells, by reducing autophagy, increased ROS and induced ER stress, promoting the release of inflammatory cytokines such as IL-6 and IL-1ß and activating pathways such as STAT3, NF-kB and mTOR. Moreover, HHV-6A infection increased the production of CXCL13, a B lymphocyte attracting chemokine, whose recruitment in the CNS could further enhance neuroinflammation. Interestingly, HHV-6A also increased the release of cathepsin S by infected astrocytoma cells as well as by primary neurons. As this enzyme is involved in the degradation of MBP, this effect could contribute to the onset/progression of MS, a neurodegenerative disease that, besides inflammation, is characterized by a progressive demyelination process. In conclusion, this study unveils new molecular mechanisms through which HHV-6A may promote important aspects involved in several neurodegenerative diseases.
Sujet(s)
Autophagie , Cathepsines/métabolisme , Cytokines/métabolisme , Stress du réticulum endoplasmique , Neurones/virologie , Infections à roséolovirus/immunologie , Système nerveux central/cytologie , Herpèsvirus humain de type 6/pathogénicité , Humains , Inflammation , Maladies neurodégénératives , Neurones/immunologieRÉSUMÉ
INTRODUCTION: This study investigated the spontaneous clinical course of patients with endomyocardial biopsy (EMB)-proven lymphocytic myocarditis and cardiac human herpesvirus 6 (HHV6) DNA presence, and the effectiveness of steroid-based intervention in HHV6-positive patients. RESULTS: 756 heart failure (HF) patients underwent an EMB procedure to determine the underlying cause of unexplained HF. Low levels of HHV6 DNA, detectable by nested PCR only, were found in 10.4% of the cases (n = 79) of which 62% (n = 49) showed myocardial inflammation. The spontaneous course of patients with EMB-proven HHV6 DNA-associated lymphocytic myocarditis (n = 26) showed significant improvements in the left ventricular ejection fraction (LVEF) and clinical symptoms, respectively, in 15/26 (60%) patients, 3-12 months after disease onset. EMB mRNA expression of components of the NLRP3 inflammasome pathway and protein analysis of cardiac remodeling markers, analyzed by real-time PCR and MALDI mass spectrometry, respectively, did not differ between HHV6-positive and -negative patients. In another cohort of patients with ongoing symptoms related to lymphocytic myocarditis associated with cardiac levels of HHV6-DNA copy numbers <500 copies/µg cardiac DNA, quantified by real-time PCR, the efficacy and safety of steroid-based immunosuppression for six months was investigated. Steroid-based immunosuppression improved the LVEF (≥5%) in 8/10 patients and reduced cardiac inflammation in 7/10 patients, without an increase in cardiac HHV6 DNA levels in follow-up EMBs. CONCLUSION: Low HHV6 DNA levels are frequently detected in the myocardium, independent of inflammation. In patients with lymphocytic myocarditis with low levels of HHV6 DNA, the spontaneous clinical improvement is nearby 60%. In selected symptomatic patients with cardiac HHV6 DNA copy numbers less than 500 copies/µg cardiac DNA and without signs of an active systemic HHV6 infection, steroid-based therapy was found to be effective and safe. This finding needs to be further confirmed in large, randomized trials.
Sujet(s)
Herpèsvirus humain de type 6/physiologie , Immunosuppresseurs/administration et posologie , Myocardite/traitement médicamenteux , Myocardite/virologie , Infections à roséolovirus/traitement médicamenteux , Infections à roséolovirus/virologie , Stéroïdes/administration et posologie , Adulte , Sujet âgé , Biopsie , Études de cohortes , ADN viral/génétique , Femelle , Dosage génique , Herpèsvirus humain de type 6/génétique , Herpèsvirus humain de type 6/isolement et purification , Humains , Mâle , Adulte d'âge moyen , Myocardite/immunologie , Myocardite/physiopathologie , Protéine-3 de la famille des NLR contenant un domaine pyrine/génétique , Protéine-3 de la famille des NLR contenant un domaine pyrine/immunologie , Infections à roséolovirus/immunologie , Infections à roséolovirus/physiopathologie , Débit systoliqueRÉSUMÉ
Human endogenous retrovirus W family envelope proteins (pHERV-W ENV/syncytin-1) have been repeatedly associated with multiple sclerosis (MS). Here, we have focused on the study of pHERV-W ENV/syncytin-1 expression levels in MS patients (relapsing and progressive forms) and in healthy donors (HD) and on exploring their possible relationship with Epstein-Barr virus (EBV) and human herpesvirus-6A/B (HHV-6A/B). We included blood samples from 101 MS patients and 37 HD to analyze antiviral antibody titers by ELISA and pHERV-W ENV/syncytin-1 expression levels by flow cytometry as well as by qPCR. Patients with relapsing MS forms showed significantly higher pHERV-W ENV/syncytin-1 protein and gene expression levels than HD. Progressive MS patients also showed significantly higher protein and gene expression levels than both HD and relapsing MS patients. Regarding antiviral antibodies titers, anti-HHV-6A/B IgM levels were positively correlated with pHERV-W ENV/syncytin-1 protein expression levels in patients with relapsing MS, while in the progressive forms patients this correlation was found with anti-HHVA/B IgG levels. Therefore, pHERV-W ENV could be involved in MS pathogenesis, playing a role in relapsing and progressive forms. Besides, anti-HHV-6A/B antibodies positively correlated with pHERV-W ENV expression. Further studies are needed to better understand this possible relationship.
Sujet(s)
Rétrovirus endogènes/physiologie , Infections à virus Epstein-Barr/immunologie , Herpèsvirus humain de type 4/physiologie , Herpèsvirus humain de type 6/physiologie , Sclérose en plaques/immunologie , Infections à roséolovirus/immunologie , Adulte , Anticorps antiviraux/sang , Évolution de la maladie , Femelle , Régulation de l'expression des gènes viraux , Produits du gène env/génétique , Produits du gène env/métabolisme , Humains , Immunoglobuline G/sang , Immunoglobuline M/sang , Mâle , Adulte d'âge moyen , Sclérose en plaques/virologie , Protéines de la grossesse/génétique , Protéines de la grossesse/métabolismeRÉSUMÉ
The coevolution of the human immune system and herpesviruses led to the emergence and diversification of both cellular danger molecules recognized by immune cells on the one hand and viral countermeasures that prevent the expression of these proteins on infected cells on the other. There are eight ligands for the activating receptor NKG2D in humans - MICA, MICB, ULBP1-6. Several of them are induced and surface-expressed on herpesvirus-infected cells to serve as danger signals to activate the immune system. Therefore, these ligands are frequently targeted for suppression by viral immune evasion mechanisms. Mechanisms to downregulate NKG2D ligands and thereby escape immune recognition have been identified in all other human herpesviruses (HHV), except for HHV-6A. In this study, we identify two HHV-6A encoded immunoevasins, U20 and U21, which suppress the expression of the NKG2D ligands ULBP1 and ULBP3, respectively, during infection. Additionally, MICB is targeted by a so far unexplored viral protein. Due to the diminished NKG2D ligand surface expression on infected cells, recognition of HHV-6A infected cells by innate immune cells is impaired. Importantly, our study indicates that immune escape mechanisms between the related herpesviruses HHV-6A and HHV-6B are evolutionary conserved as the same NKG2D ligands are targeted. Our data contribute an additional piece of evidence for the importance of the NKG2D receptor - NKG2D ligand axis during human herpesvirus infections and sheds light on immune evasion mechanisms of HHV-6A.
Sujet(s)
Protéines liées au GPI/métabolisme , Herpèsvirus humain de type 6/physiologie , Interactions hôte-pathogène/immunologie , Infections à roséolovirus/immunologie , Infections à roséolovirus/métabolisme , Infections à roséolovirus/virologie , Protéines virales/métabolisme , Cytométrie en flux , Protéines liées au GPI/génétique , Régulation de l'expression des gènes , Antigènes d'histocompatibilité de classe I/génétique , Antigènes d'histocompatibilité de classe I/métabolisme , Interactions hôte-pathogène/génétique , Humains , Échappement immunitaire , Protéines et peptides de signalisation intercellulaire/génétique , Protéines et peptides de signalisation intercellulaire/métabolisme , Protéines et peptides de signalisation intracellulaire/génétique , Protéines et peptides de signalisation intracellulaire/métabolisme , Ligands , Sous-famille K des récepteurs de cellules NK de type lectine/métabolisme , Liaison aux protéinesRÉSUMÉ
Viral infection induces host cells to mount a variety of immune responses, which may either limit viral propagation or create conditions conducive to virus replication in some instances. In this regard, activation of the NF-κB transcription factor is known to modulate virus replication. Human herpesvirus 6A (HHV-6A), which belongs to the Betaherpesvirinae subfamily, is frequently found in patients with neuroinflammatory diseases, although its role in disease pathogenesis has not been elucidated. In this study, we found that the HHV-6A-encoded U14 protein activates NF-κB signaling following interaction with the NF-κB complex protein, p65. Through induction of nuclear translocation of p65, U14 increases the expression of interleukin-6 (IL-6), IL-8, and monocyte chemoattractant protein 1 transcripts. We also demonstrated that activation of NF-κB signaling is important for HHV-6A replication, since inhibition of this pathway reduced virus protein accumulation and viral genome copy number. Taken together, our results suggest that HHV-6A infection activates the NF-κB pathway and promotes viral gene expression via late gene products, including U14. IMPORTANCE Human herpesvirus 6A (HHV-6A) is frequently found in patients with neuro-inflammation, although its role in the pathogenesis of this disease has not been elucidated. Most viral infections activate the NF-κB pathway, which causes the transactivation of various genes, including those encoding proinflammatory cytokines. Our results indicate that HHV-6A U14 activates the NF-κB pathway, leading to upregulation of proinflammatory cytokines. We also found that activation of the NF-κB transcription factor is important for efficient viral replication. This study provides new insight into HHV-6A U14 function in host cell signaling and identifies potential cellular targets involved in HHV-6A pathogenesis and replication.
Sujet(s)
Herpèsvirus humain de type 6/génétique , Herpèsvirus humain de type 6/métabolisme , Facteur de transcription NF-kappa B/métabolisme , Infections à roséolovirus/immunologie , Transduction du signal/immunologie , Protéines virales/immunologie , Lignée cellulaire , Régulation de l'expression des gènes , Gènes viraux , Génome viral , Humains , Facteur de transcription NF-kappa B/génétique , Maladies neuro-inflammatoires , Récepteur EphB2 , Protéines virales/génétique , Réplication viraleRÉSUMÉ
A vaccine against congenital cytomegalovirus infection is a high priority. Guinea pig cytomegalovirus (GPCMV) is the only congenital CMV small animal model. GPCMV encodes essential glycoprotein complexes for virus entry (gB, gH/gL/gO, gM/gN) including a pentamer complex (gH/gL/GP129/GP131/GP133 or PC) for endocytic cell entry. The cohorts for protection against congenital CMV are poorly defined. Neutralizing antibodies to the viral glycoprotein complexes are potentially more important than an immunodominant T-cell response to the pp65 protein. In GPCMV, GP83 (pp65 homolog) is an evasion factor, and the GP83 mutant GPCMV has increased sensitivity to type I interferon. Although GP83 induces a cell-mediated response, a GP83-only-based vaccine strategy has limited efficacy. GPCMV attenuation via GP83 null deletion mutant in glycoprotein PC positive or negative virus was evaluated as live-attenuated vaccine strains (GP83dPC+/PC-). Vaccinated animals induced antibodies to viral glycoprotein complexes, and PC+ vaccinated animals had sterilizing immunity against wtGPCMV challenge. In a pre-conception vaccine (GP83dPC+) study, dams challenged mid-2nd trimester with wtGPCMV had complete protection against congenital CMV infection without detectable virus in pups. An unvaccinated control group had 80% pup transmission rate. Overall, gB and PC antibodies are key for protection against congenital CMV infection, but a response to pp65 is not strictly necessary.
Sujet(s)
Anticorps neutralisants/immunologie , Infections à cytomégalovirus/prévention et contrôle , Cytomegalovirus/immunologie , Roseolovirus/immunologie , Lymphocytes T/immunologie , Protéines de l'enveloppe virale/immunologie , Protéines de la matrice virale/immunologie , Vaccins antiviraux/administration et posologie , Animaux , Anticorps antiviraux/immunologie , Cytomegalovirus/génétique , Infections à cytomégalovirus/congénital , Infections à cytomégalovirus/immunologie , Infections à cytomégalovirus/virologie , Femelle , Cochons d'Inde , Humains , Mâle , Roseolovirus/génétique , Infections à roséolovirus/congénital , Infections à roséolovirus/immunologie , Infections à roséolovirus/prévention et contrôle , Infections à roséolovirus/virologie , Vaccination , Protéines de l'enveloppe virale/administration et posologie , Protéines de l'enveloppe virale/génétique , Protéines de la matrice virale/administration et posologie , Protéines de la matrice virale/génétique , Vaccins antiviraux/génétique , Vaccins antiviraux/immunologieRÉSUMÉ
Human herpesviruses 6A (HHV-6A) and human herpesvirus 6B (HHV-6B)-collectively, HHV-6A/B-are recently-discovered but ancient human viruses. The vast majority of people acquire one or both viruses, typically very early in life, producing an ineradicable lifelong infection. The viruses have been linked to several neurological, pulmonary and hematological diseases. In early human history, the viruses on multiple occasions infected a germ cell, and integrated their DNA into a human chromosome. As a result, about 1% of humans are born with the full viral genome present in every cell, with uncertain consequences for health. HHV-6A may play a role in 43% of cases of primary unexplained infertility. Both the inherited and acquired viruses may occasionally trigger several of the factors that are important in the pathogenesis of preeclampsia. Transplacental infection occurs in 1-2% of pregnancies, with some evidence suggesting adverse health consequences for the child. While emerging knowledge about these viruses in reproductive diseases is not sufficient to suggest any changes in current practice, we write this review to indicate the need for further research that could prove practice-changing.
Sujet(s)
Avortement spontané/immunologie , Retard de croissance intra-utérin/immunologie , Herpèsvirus humain de type 6/immunologie , Infections à roséolovirus/immunologie , Intégration virale/immunologie , Réplication virale/immunologie , Avortement spontané/virologie , Col de l'utérus/cytologie , Col de l'utérus/immunologie , Col de l'utérus/virologie , Femelle , Retard de croissance intra-utérin/virologie , Herpèsvirus humain de type 6/génétique , Herpèsvirus humain de type 6/physiologie , Humains , Placenta/cytologie , Placenta/immunologie , Placenta/virologie , Grossesse , Infections à roséolovirus/virologie , Intégration virale/génétique , Réplication virale/génétiqueRÉSUMÉ
BACKGROUND: Naïve T-cell-depleted grafts have been employed as an ex vivo T-cell depletion (TCD) platform to prevent graft-versus-host disease (GvHD) and improve immune reconstitution by providing rapid donor memory T-cell reconstitution after allogenic hematopoietic stem cell transplantation (allo-HSCT). CD45RA- memory T cells confer protection against viruses such as cytomegalovirus, Epstein-Barr virus, and adenovirus; however, reports have shown an unexpectedly high incidence of human herpesvirus (HHV)-6B encephalitis among pediatric allo-HSCT patients. METHODS: We report the first 18 consecutive allo-HSCT, 16 haplo-HSCT, and two human leukocyte antigen-matched related donors implanted with naïve TCD grafts. All donors were administered three cell products: first, a CD34+ stem cell product; second, a CD45RA+ TCD graft, followed by an adoptive natural killer (NK) cell infusion within 10 days after HSCT. The study's primary endpoint was the incidence of HHV-6B encephalitis. RESULTS: Engraftment was achieved in 94.5% of cases; 2-year overall survival, event-free survival, and GvHD/relapse-free survival were 87.2% (95% CI 78.6-95.8), 67.3% (95% CI 53.1-81.5), and 64% (95% CI 50.5-78.1), respectively. HHV-6B reactivation occurred in 7 of the haplo-HSCT patients, six of who received a cell infusion with an NK/CD4 ratio <2. None of the patients developed encephalitis. CONCLUSIONS: In this clinical study, we show that early adoptive NK cell infusion after a 45RA+ TCD allo-HSCT graft is safe and can prevent HHV-6B encephalitis. We recommend infusing adoptive NK cells after allo-HSCT using CD45RA+ TCD grafts.
Sujet(s)
Encéphalite/prévention et contrôle , Transplantation de cellules souches hématopoïétiques , Herpèsvirus humain de type 6/isolement et purification , Cellules tueuses naturelles/transplantation , Déplétion lymphocytaire , Infections à roséolovirus/prévention et contrôle , Adolescent , Transfert adoptif/méthodes , Enfant , Enfant d'âge préscolaire , Encéphalite/immunologie , Femelle , Maladie du greffon contre l'hôte/immunologie , Maladie du greffon contre l'hôte/prévention et contrôle , Transplantation de cellules souches hématopoïétiques/méthodes , Herpèsvirus humain de type 6/immunologie , Humains , Nourrisson , Cellules tueuses naturelles/immunologie , Mâle , Infections à roséolovirus/immunologie , Lymphocytes T/immunologie , Transplantation homologue/méthodesRÉSUMÉ
During persistent human beta-herpesvirus (HHV) infection, clinical manifestations may not appear. However, the lifelong influence of HHV is often associated with pathological changes in the central nervous system. Herein, we evaluated possible associations between immunoexpression of HHV-6, -7, and cellular immune response across different brain regions. The study aimed to explore HHV-6, -7 infection within the cortical lobes in cases of unspecified encephalopathy (UEP) and nonpathological conditions. We confirmed the presence of viral DNA by nPCR and viral antigens by immunohistochemistry. Overall, we have shown a significant increase (p < 0.001) of HHV antigen expression, especially HHV-7 in the temporal gray matter. Although HHV-infected neurons were found notably in the case of HHV-7, our observations suggest that higher (p < 0.001) cell tropism is associated with glial and endothelial cells in both UEP group and controls. HHV-6, predominantly detected in oligodendrocytes (p < 0.001), and HHV-7, predominantly detected in both astrocytes and oligodendrocytes (p < 0.001), exhibit varying effects on neural homeostasis. This indicates a high number (p < 0.001) of activated microglia observed in the temporal lobe in the UEP group. The question remains of whether human HHV contributes to neurological diseases or are markers for some aspect of the disease process.
Sujet(s)
Encéphalopathies/immunologie , Herpèsvirus humain de type 6 , Herpèsvirus humain de type 7 , Immunité cellulaire , Névroglie/virologie , Infections à roséolovirus/immunologie , Adulte , Sujet âgé , Antigènes viraux/analyse , Astrocytes/virologie , Encéphale/immunologie , Encéphale/virologie , Encéphalopathies/virologie , Cellules endothéliales/virologie , Femelle , Humains , Immunohistochimie , Mâle , Adulte d'âge moyen , Oligodendroglie/virologieRÉSUMÉ
OBJECTIVE: The aim of this study was to analyze the clinical, radiologic, and biological features associated with human herpesvirus 6 (HHV-6) encephalitis in immunocompetent and immunocompromised hosts to establish which clinical settings should prompt HHV-6 testing. METHODS: We performed a retrospective research in the virology database of Fondazione IRCCS Policlinico San Matteo (Pavia, Italy) for all patients who tested positive for HHV-6 DNA in the CSF and/or in blood from January 2008 to September 2018 and separately assessed the number of patients meeting the criteria for HHV-6 encephalitis in the group of immunocompetent and immunocompromised hosts. RESULTS: Of the 926 patients tested for HHV-6 during the period of interest, 45 met the study criteria. Among immunocompetent hosts (n = 17), HHV-6 encephalitis was diagnosed to 4 infants or children presenting with seizures or mild encephalopathy during primary HHV-6 infection (CSF/blood replication ratio <<1 in all cases). Among immunocompromised hosts (n = 28), HHV-6 encephalitis was diagnosed to 7 adolescents/adults with hematologic conditions presenting with altered mental status (7/7), seizures (3/7), vigilance impairment (3/7), behavioral changes (2/7), hyponatremia (2/7), and anterograde amnesia (1/7). Initial brain MRI was altered only in 2 patients, but 6 of the 7 had a CSF/blood replication ratio >1. CONCLUSIONS: The detection of a CSF/blood replication ratio >1 represented a specific feature of immunocompromised patients with HHV-6 encephalitis and could be of special help to establish a diagnosis of HHV-6 encephalitis in hematopoietic stem cell transplant recipients lacking radiologic evidence of limbic involvement.
Sujet(s)
Encéphalite virale/liquide cérébrospinal , Encéphalite virale/virologie , Transplantation de cellules souches hématopoïétiques , Herpèsvirus humain de type 6/pathogénicité , Infections à roséolovirus/liquide cérébrospinal , Infections à roséolovirus/virologie , Adolescent , Adulte , Antiviraux/liquide cérébrospinal , Antiviraux/pharmacologie , Encéphalite virale/immunologie , Femelle , Transplantation de cellules souches hématopoïétiques/méthodes , Herpèsvirus humain de type 6/génétique , Herpèsvirus humain de type 6/immunologie , Humains , Sujet immunodéprimé/immunologie , Mâle , Études rétrospectives , Infections à roséolovirus/immunologie , Crises épileptiques/immunologie , Crises épileptiques/thérapie , Crises épileptiques/virologie , Jeune adulteRÉSUMÉ
BACKGROUND: Serious neurological complications of SARS-CoV-2 are increasingly being recognized. CASE: We report a novel case of HHV6 myelitis with parainfectious MOG-IgG in the setting of COVID-19-induced lymphopenia and hypogammaglobulinemia. The patient experienced complete neurological recovery with gancyclovir, high dose corticosteroids, and plasma exchange. To our knowledge, this is the first case of HHV6 reactivation in the central nervous system in the setting of COVID19 infection and the first case of MOG-IgG myelitis in the setting of SARS-CoV-2 and HHV6 coinfection. CONCLUSION: Patients with neurological manifestations in the setting of COVID19-related immunodeficiency should be tested for opportunistic infections including HHV6. Viral infection is a known trigger for MOG-IgG and therefore this antibody should be checked in patients with SARS-CoV-2 associated demyelination.
Sujet(s)
COVID-19/complications , Co-infection/complications , Lymphopénie/virologie , Myélite transverse/virologie , Infections à roséolovirus/immunologie , Anti-inflammatoires/usage thérapeutique , Antiviraux/usage thérapeutique , Autoanticorps/immunologie , Autoantigènes/immunologie , COVID-19/immunologie , Co-infection/immunologie , Ganciclovir/usage thérapeutique , Herpèsvirus humain de type 6 , Humains , Mâle , Méthylprednisolone/usage thérapeutique , Adulte d'âge moyen , Myélite transverse/immunologie , Myélite transverse/thérapie , Échange plasmatique/méthodes , Infections à roséolovirus/traitement médicamenteux , SARS-CoV-2 , Activation virale/immunologieRÉSUMÉ
Programmed death ligand 1 (PD-L1) up-regulation on antigen presenting cells induces T cell dysfunction, strongly impairing immune response. Human Herpesviruses (HHV) 6B is a ß-herpesvirus that, although displays a higher tropism for T cells, can infect other immune cells including monocytes and dendritic cells (DCs) and neuronal cells. We have previously shown that HHV-6B infection of primary monocytes reduced autophagy and induced Endoplasmic Reticulum (ER) stress/ Unfolded Protein Response (UPR), impairing their survival and differentiation into DCs. In this study, we found that PD-L1 expression was up-regulated by HHV-6B on the surface of infected monocytes and that its extracellular release also increased, effects known to lead to an impairment of anti-viral immune response. At molecular level, PD-L1 up-regulation correlated with the activation of a positive regulatory circuit between the increase of intracellular ROS and the activation of STAT1 and STAT3 induced by HHV-6B, accompanied by a high release of pro-inflammatory/immune suppressive cytokines. In conclusion, this study unveils new strategies put in place by HHV-6B to induce immune dysfunction and the underlying molecular pathways that could be targeted to counteract such immune suppressive effects.